Lantheus Holdings, Inc.
Moat Score — Lantheus Holdings, Inc.
Total Moat Score
15 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Lantheus holds exclusive licenses and regulatory approvals underpinning PYLARIFY's PSMA-ligand technology and DEFINITY's formulation, backed by FDA approvals that are costly and time-consuming for rivals to replicate even as patent exclusivity narrows. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 3 / 5 | Lantheus's distributed F-18/Ga-68 manufacturing network (PMFs), built to handle short-half-life isotopes, gives it an established logistics cost and speed advantage over new entrants who must build comparable regional production and distribution infrastructure from scratch. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | Lantheus has commanded premium reimbursement for PYLARIFY as the first-to-scale PSMA PET agent and holds over 80% U.S. share in DEFINITY, though pricing power on PYLARIFY is already eroding as Telix and Blue Earth Diagnostics gain share ahead of the 2026 exclusivity cliff. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect: a hospital's or patient's outcome with PYLARIFY or DEFINITY does not improve because more hospitals or patients use Lantheus's agents. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Referring physicians and imaging protocols build familiarity around a specific tracer, and hospital procurement/formulary processes create some friction, but switching to a clinically comparable competing PSMA or ultrasound agent is not prohibitively difficult once a rival agent is approved and stocked. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | The short half-life of F-18 and Ga-68 isotopes requires a dense national network of regional manufacturing sites to serve hospitals reliably, a capital and logistics barrier that limits how quickly new entrants can achieve nationwide coverage comparable to Lantheus's existing PMF network. |